The Patent Finder

Teikoku Pharma USA, Inc.

19 patents currently held · Updated Nov 18, 2026
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Oct 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 23, 2027
    The maintenance fee for Rivastigmine transdermal compositions and methods of using the same (US 10,357,463) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
  • 1 fee due Mar 29, 2027
    The maintenance fee for Compositions and methods for transdermal delivery of hormones and other medicinal agents (US 9,144,553) comes due Mar 29, 2027. Unpaid by Sep 29, 2027, it lapses early.
  • 1 fee due Jun 8, 2027
    The maintenance fee for Propynylaminoindan transdermal compositions (US 9,205,061) comes due Jun 8, 2027. Unpaid by Dec 8, 2027, it lapses early.
  • 2 fees due Oct 12 to 14, 2027 · next Oct 12

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,006,280Pyrazolone derivative formulations
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,842,770Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,569,357Taxane pro-emulsion formulations and methods making and using the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,940,786Non-aqueous taxane nanodispersion formulations and methods of using the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,308,195Non-aqueous taxane formulations and methods of using the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,763,880Non-aqueous taxane formulations and methods of using the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,205,061Propynylaminoindan transdermal compositions
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,918,607Propynylaminoindan transdermal compositions
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,827,207Propynylaminoindan transdermal compositions
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,144,553Compositions and methods for transdermal delivery of hormones and other medicinal agents
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
Also on record, not counted in the 19: 9 patents in force now held by others · 25 lapsed for an unpaid fee · 17 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 3 abandoned · 13 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited